Dr Iveson speaks with ecancer at ASCO 2017 about results from the SCOT trial, a noninferiority assessment of adjuvant oxaliplatin chemotherapy for 3 or 6 months to treat colorectal cancer.

He describes how, by meeting these noninferiority endpoints, 3 months of oxaliplatin can reduce cost for healthcare providers and improve patient quality of life, with less risk of peripheral neuropathy.

The SCOT trial contributes to a larger international trial schema called IDEA, an international collaborative assessment of oxaliplatin with capecitabine or FOLFIRI at different fractions and staging.

Findings within IDEA have identified high and low risk groups, Dr Iveson encourages to be considered eligible for 3 months CapOx.